- Home
- MNMD
as 07-26-2024 4:00pm EST
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 562.0M | IPO Year: | N/A |
| Target Price: | $25.86 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.41 - $12.22 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Jun 25 '24 | Sell | $7.22 | 17,854 | $128,905.88 | 182,146 | SEC Form 4 |
| Barrow Robert | MNMD | Chief Executive Officer | Jun 25 '24 | Sell | $7.22 | 15,659 | $113,057.98 | 564,543 | SEC Form 4 |
| Karlin Dan | MNMD | Chief Medical Officer | Jun 25 '24 | Sell | $7.22 | 6,925 | $49,998.50 | 351,527 | SEC Form 4 |
| Karlin Dan | MNMD | Chief Medical Officer | Mar 25 '24 | Sell | $9.50 | 6,578 | $62,491.00 | 358,452 | SEC Form 4 |
| Barrow Robert | MNMD | Chief Executive Officer | Mar 25 '24 | Sell | $9.50 | 16,519 | $156,930.50 | 580,202 | SEC Form 4 |
| Greenway Schond L. | MNMD | Chief Financial Officer | Dec 26 '23 | Sell | $3.63 | 5,652 | $20,516.76 | 216,617 | SEC Form 4 |
| Barrow Robert | MNMD | Chief Executive Officer | Dec 26 '23 | Sell | $3.63 | 13,237 | $48,050.31 | 596,721 | SEC Form 4 |
| Karlin Dan | MNMD | Chief Medical Officer | Dec 26 '23 | Sell | $3.63 | 6,774 | $24,589.62 | 365,030 | SEC Form 4 |
Latest Mind Medicine (MindMed) Inc. News
MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
Business Wire
a month ago
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
Business Wire
a month ago
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Business Wire
a month ago
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Compare MNMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.